^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | Zirabev (bevacizumab-bvzr) (VEGF-A inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
02/14/2019
Excerpt:
Zirabev in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer.
Secondary therapy:
paclitaxel
